Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients

Journal of Infectious Diseases

Volumn 204, Issue 3, 2011, Pages 408-414

  Chan, Henry Lik Yuen ^a   Wong, Grace Lai Hung ^a   Tse, Chi Hang ^a   Chan, Hoi Yun ^a   Wong, Vincent Wai Sun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATHOGEN CLEARANCE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SEROLOGY;

ALANINE TRANSAMINASE; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; LONGITUDINAL STUDIES;

EID: 79960113229     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir283     Document Type: Article

References (35)

1. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26:153-61. (Pubitemid 43668257)
2. Chan HL, Wong GL, Wong VW. A review of the natural history of chronic hepatitis B in the era of transient elastography. Antivir Ther 2009; 14:489-99.
3. Chan HL, Hui Y, Leung NW, Ching JL, Chan FK, Sung JJ. Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients. Am J Gastroenterol 2000; 95:3547-51.
4. Sung JJ, Chan HL, Wong ML, et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepat 2002; 9:229-34. (Pubitemid 36005522)
5. Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody-positive patients. Hepatology 1987; 7:20-3.
6. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-86. (Pubitemid 43374518)
7. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
8. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26:177-82.
9. Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28:1660-5.
10. Liaw YF, Leung NW, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2:263-83.
11. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-42.
12. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-39. (Pubitemid 46374607)
13. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36:1408-15. (Pubitemid 35407438)
14. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008; 15:434-41. (Pubitemid 351677546)
15. Chan HL, Wong ML, Hui AY, Hung LC, Chan FK, Sung JJ. Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B. J Clin Microbiol 2003; 41:4793-5. (Pubitemid 37259797)
16. Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138:1747-54.
17. Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 139:474-82.
18. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45:1187-92.
19. Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135:1192-9.
20. Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51:1531-7.
21. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-8. (Pubitemid 38736340)
22. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5:1462-8. (Pubitemid 350181604)
23. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum HBsAg changes in chronic hepatitis B. Hepatology 2010; 52:1232-41.
24. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with increased risk of hepatocellular carcinoma. Gut 2004; 53:1494-8. (Pubitemid 39265273)
25. Chan HL, Chui AK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68:182-7.
26. Chan HL, Tsang SW, Liew CT, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97:406-12. (Pubitemid 34160768)
27. Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during HBeAg seroconversion. Hepatology 1999; 29:976-84. (Pubitemid 29109618)
28. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52:508-13.
29. Jaroszewicz J, Serrano BC, Wursthon K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (JBV)-infection: a European perspective. J Hepatol 2010; 52:514-22.
30. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis virus markers. Hepatology 2010; 51:1933-44.
31. Lin LY, Wong VW, Zhou HJ, et al. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. J Med Virol 2010; 82:1494-500.
32. Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133:843-52. (Pubitemid 47374140)
33. Larus A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006; 44:694-702. (Pubitemid 44433726)
34. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139:483-90.
35. Chan HL, Wong GL, Tse CH, Chim AM, Lai HL, Sung JJ. HBV genotype C is associated with more severe fibrosis than genotype B. Clin Gastroenterol Hepatol 2009; 7:1361-6.